Caribou Biosciences, Inc. (CRBU)
| Previous Close | 3.5000 |
| Open | 3.5000 |
| Bid | 3.6500 x 100 |
| Ask | 3.6600 x 200 |
| Day's Range | 3.5000 - 3.6950 |
| 52 Week Range | 3.4400 - 8.5900 |
| Volume | |
| Avg. Volume | 1,645,118 |
| Market Cap | 330.112M |
| Beta (5Y Monthly) | 2.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.75 |
Simply Wall St.Caribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are probably feeling a little disappointed, since its shares...
ZacksCaribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCaribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash
